Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 109.74 -2.27 (-2.03%) Market Cap: 6.92 Bil Enterprise Value: 11.03 Bil PE Ratio: 22.63 PB Ratio: 1.87 GF Score: 78/100

Jazz Pharmaceuticals PLC Acquisition of Cavion Inc - M&A Call Transcript

Aug 12, 2019 / 09:00PM GMT
Release Date Price: $136.67 (-0.51%)
Operator

Welcome to the Jazz Pharmaceuticals plc Investor Update Acquisition of Cavion, Inc., Conference Call. Following an introduction from the company, we will open the call to questions.

I will now turn the call over to Kathee Littrell, Head of Investor Relations at Jazz Pharmaceuticals.

Katherine A. Littrell
Jazz Pharmaceuticals plc - VP of IR

Thank you, Carmen, and thank you for joining our investor call today to discuss the acquisition of Cavion and its key product, CX-8998. The press release and the slide presentation accompanying this call are available on the Investor section of our website.

I'd like to remind you that some of the statements we will make on this call relate to future events and performance rather than historical facts and are forward-looking. Examples include statements regarding our future development plans and opportunities for CX-8998. These forward-looking statements involve risks and uncertainties that could cause actual events, performance and results to differ materially. We undertake no duty or obligation to update

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot